Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Interest Expenses (2020 - 2024)

Whitehawk Therapeutics (WHWK) has disclosed Interest Expenses for 5 consecutive years, with $38000.0 as the latest value for Q3 2024.

  • Quarterly Interest Expenses fell 34.48% to $38000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $38000.0 through Jun 2025, down 83.55% year-over-year, with the annual reading at $154000.0 for FY2024, 33.33% down from the prior year.
  • Interest Expenses for Q3 2024 was $38000.0 at Whitehawk Therapeutics, down from $58000.0 in the prior quarter.
  • The five-year high for Interest Expenses was $229000.0 in Q3 2020, with the low at $38000.0 in Q3 2024.
  • Average Interest Expenses over 5 years is $94375.0, with a median of $58000.0 recorded in 2022.
  • Peak annual rise in Interest Expenses hit 0.0% in 2022, while the deepest fall reached 74.45% in 2022.
  • Over 5 years, Interest Expenses stood at $229000.0 in 2020, then plummeted by 75.11% to $57000.0 in 2021, then changed by 0.0% to $57000.0 in 2022, then changed by 0.0% to $57000.0 in 2023, then plummeted by 33.33% to $38000.0 in 2024.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $38000.0, $58000.0, and $58000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.